Use of inhibitors of Bruton's tyrosine kinase (Btk)
View Patent ↗Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
1. A method for treating Waldenström's macroglobulinemia in an individual in need thereof, wherein the individual is treatment-nave for Waldenström's macroglobulinemia, comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
2. The method of claim 1 , wherein the oral dose is a capsule.
3. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a stable disease, a partial response, or a complete response.
4. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.
5. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a complete response.
6. The method of claim 1 , wherein, following administration of the inhibitor, the individual does not experience a progressive disease.
7. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a stable disease.
8. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a partial response.